Company Description
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases.
Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees.
Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 7, 2022 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 136 |
| CEO | Joshua B. Cohen |
Contact Details
Address: 55 Cambridge Parkway, Suite 6W Cambridge, Massachusetts 02142 United States | |
| Phone | 617 682 0917 |
| Website | amylyx.com |
Stock Details
| Ticker Symbol | AMLX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 1658551 |
| CUSIP Number | 03237H101 |
| ISIN Number | US03237H1014 |
| Employer ID | 46-4600503 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Justin B. Klee | Co-Founder, Co-Chief Executive Officer and Director |
| Joshua B. Cohen | Co-Founder, Co-Chief Executive Officer and Director |
| James M. Frates M.B.A. | Chief Financial Officer |
| Gina M. Mazzariello J.D. | Chief Legal Officer and General Counsel |
| Tom Holmes | Chief Technical Operations Officer |
| Lindsey Allen | Head of Investor Relations and Communications |
| Linda A. Arsenault | Chief Human Resources Officer |
| Tammy Sarnelli | Global Head of Regulatory Affairs |
| Dr. Machelle Manuel Ph.D. | Vice President and Head of Global Medical Affairs |
| Dr. Jamie Timmons | Head of Global Medical Strategy and Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 3, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 3, 2026 | 10-K | Annual Report |
| Mar 3, 2026 | 8-K | Current Report |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Feb 23, 2026 | 144 | Filing |